American journal of clinical pathology最新文献_第8页

Urothelial carcinoma with osteoclast-like giant cells: An expanded immunohistochemical and molecular profile. 尿路上皮癌伴破骨细胞样巨细胞：扩大免疫组织化学和分子图谱。

IF 1.9 4区医学

American journal of clinical pathology Pub Date : 2025-08-26 DOI: 10.1093/ajcp/aqaf044

Carol N Rizkalla, Maria Tretiakova, Carlos J Suarez, Sean R Williamson, Khaleel I Al-Obaidy, Andres M Acosta, Muhammad T Idrees, Emily Chan, Susan Potterveld, Ankur R Sangoi

{"title":"Urothelial carcinoma with osteoclast-like giant cells: An expanded immunohistochemical and molecular profile.","authors":"Carol N Rizkalla, Maria Tretiakova, Carlos J Suarez, Sean R Williamson, Khaleel I Al-Obaidy, Andres M Acosta, Muhammad T Idrees, Emily Chan, Susan Potterveld, Ankur R Sangoi","doi":"10.1093/ajcp/aqaf044","DOIUrl":"10.1093/ajcp/aqaf044","url":null,"abstract":"Objective: Osteoclast-rich undifferentiated carcinoma of the urinary tract, herein referred to as urothelial carcinoma with osteoclast-like giant cells (UCOGC), is a rare tumor currently classified under the \"poorly differentiated urothelial carcinoma\" subtype. This study aimed to evaluate the clinicopathologic, immunophenotypic, and molecular features of UCOGC to better characterize its origin and support its classification as a unique subtype.Methods: There were 14 UCOGCs studied with immunohistochemistry/in situ hybridization and compared to urothelial carcinomas with trophoblastic differentiation (n = 6) and giant cell urothelial carcinomas (n = 5). Markers were assessed in mononuclear (MN) and giant cell (GC) components. Next-generation sequencing was performed on 4 UCOGCs.Results: The MN cells of UCOGC demonstrated high expression of CD68, CD163, SATB2, cathepsin K, and CSF1 in situ hybridization (ISH), with moderate staining for GATA3, p63, and PU.1 and low staining for pankeratin. The GCs showed high CD68, PU.1, and cathepsin K expression but low CD163, SATB2, and CSF1 ISH, with no staining for urothelial markers or pankeratin. Both MN and GC were negative for H3.G34W and HCG. Next-generation sequencing revealed mutations consistent with conventional urothelial carcinomas.Conclusions: The distinct biphasic morphology, characteristic immunophenotype, and molecular findings of UCOGC suggest it is of urothelial origin, and we believe it justifies its classification as a unique subtype rather than under \"poorly differentiated urothelial carcinoma.\"","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"257-264"},"PeriodicalIF":1.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144281961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinicopathologic characteristics of lymphoproliferative disorders involving the kidney. 累及肾脏的淋巴细胞增生性疾病的临床病理特征。

IF 1.9 4区医学

American journal of clinical pathology Pub Date : 2025-08-26 DOI: 10.1093/ajcp/aqaf023

Kotaro Takeda, Haiming Tang, Deepika Kumar, Adebowale J Adeniran, Guoping Cai

{"title":"Clinicopathologic characteristics of lymphoproliferative disorders involving the kidney.","authors":"Kotaro Takeda, Haiming Tang, Deepika Kumar, Adebowale J Adeniran, Guoping Cai","doi":"10.1093/ajcp/aqaf023","DOIUrl":"10.1093/ajcp/aqaf023","url":null,"abstract":"Objective: Lymphoproliferative disorders can involve the kidney, which is associated with a worse prognosis. The objective of this study was to review the clinical and histologic characteristics of patients with lymphoproliferative disorders involving the kidneys.Methods: Cases with lymphoproliferative disorders showing renal involvement were retrieved from the institutional pathology database for the past 20 years. Data regarding patient demographics, clinical presentations, lymphoma subtypes, history of lymphoma, treatments received, chemotherapy regimens, and patient outcomes were extracted.Results: The cohort included 48 cases of non-Hodgkin lymphoma with renal involvement, comprising 35 men and 13 women, with a median age of 71.5 years. Most lymphomas were mature B-cell neoplasms, accounting for 42 (87.5%) cases, with diffuse large B-cell lymphoma as the leading subtype in 18 (42.9%) cases. A renal mass was the initial presentation in 33 (68.8%) patients, while the remaining 15 (31.2%) had medical renal complications. Approximately half of the renal mass cases were de novo aggressive lymphomas, while most with renal complications had systemic involvement of previously diagnosed low-grade lymphomas. Chemotherapy, frequently R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), was the primary treatment. Patients with a kidney mass tended to show a worse prognosis than those with medical renal complications, but statistical significance was not reached (P = .347).Conclusions: The study demonstrates that renal mass is a crucial presentation of lymphoma, in some cases even without history, highlighting the importance of renal biopsy to triage patients for proper treatment and avoid unnecessary nephrectomy.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"192-199"},"PeriodicalIF":1.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of anatomic pathology and laboratory medicine diagnostic services and infrastructure available at a sample of institutions in Kenya. 分析肯尼亚样本机构的解剖病理学和实验室医学诊断服务和基础设施。

IF 1.9 4区医学

American journal of clinical pathology Pub Date : 2025-08-26 DOI: 10.1093/ajcp/aqaf021

Nicholas McKenzie, Jeremy W Jacobs, Danny A Milner, Quentin Eichbaum

{"title":"Analysis of anatomic pathology and laboratory medicine diagnostic services and infrastructure available at a sample of institutions in Kenya.","authors":"Nicholas McKenzie, Jeremy W Jacobs, Danny A Milner, Quentin Eichbaum","doi":"10.1093/ajcp/aqaf021","DOIUrl":"10.1093/ajcp/aqaf021","url":null,"abstract":"Objective: There is a paucity of data regarding the anatomic and clinical pathology capabilities at hospitals and laboratories across much of Africa, including in Kenya. We aimed to sample institutions in Kenya to identify the available pathology and laboratory diagnostic services.Methods: Subject matter experts developed 2 individual surveys assessing anatomic pathology (AP) and clinical pathology (CP), respectively. The surveys were administered to individuals involved in pathology services at hospitals and laboratories across Kenya between June and August 2022 using the American Society for Clinical Pathology email listserv.Results: Responses from 18 unique laboratories in Kenya were analyzed. Five sites provided AP services, while 17 provided CP services; 4 sites provided both AP and CP services. Cytopathology, autopsy services, and hematopathology services were available at all 5 sites that performed AP; 4 provided surgical pathology services for large resections with margins (80%); and 2 provided services for small biopsies (40%). No location had molecular testing capabilities. Among the 17 sites that provided CP services, most had the capability to perform rapid diagnostic and/or point-of-care testing (n = 14, 82%), chemistry (n = 13, 76%), microbiology (n = 13, 76%), and hematology and/or coagulation (n = 13, 76%). However, cytogenetics and flow cytometry were generally not available (n = 4, 24%).Conclusions: These findings demonstrate that, among this sample of institutions in Kenya, basic AP and CP services were frequently available. Conversely, advanced diagnostic modalities were the exception. Strategic investment to improve this capacity could contribute to optimization of the health care system in Kenya.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"182-191"},"PeriodicalIF":1.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144740901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interobserver agreement in scoring HER2-negative and HER2-low immunohistochemistry in breast cancer: Reasons for discordance and impact of a single training session. 乳腺癌中her2阴性和her2低免疫组化评分的观察者间一致性：不一致的原因和单次训练的影响

IF 1.9 4区医学

American journal of clinical pathology Pub Date : 2025-08-26 DOI: 10.1093/ajcp/aqaf043

Yun-An Tseng, Steffanie Tamayo, Evi Abada, Shivali Marketkar, Linda C Hanley, Katrine Hansen, M Ruhul Quddus, C James Sung, Kamaljeet Singh

{"title":"Interobserver agreement in scoring HER2-negative and HER2-low immunohistochemistry in breast cancer: Reasons for discordance and impact of a single training session.","authors":"Yun-An Tseng, Steffanie Tamayo, Evi Abada, Shivali Marketkar, Linda C Hanley, Katrine Hansen, M Ruhul Quddus, C James Sung, Kamaljeet Singh","doi":"10.1093/ajcp/aqaf043","DOIUrl":"10.1093/ajcp/aqaf043","url":null,"abstract":"Objective: In the DESTINY-Breast04 trial, human epidermal growth factor receptor 2 (HER2) low (HER2-L) is defined as an HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative fluorescence in situ hybridization. Limited data report poor agreement in scoring HER2-0 vs 1+. We aim to investigate the HER2 IHC concordance rate, with focus on HER2-0 vs HER2-L groups. We evaluate the impact of a single training session on concordance.Methods: Nine breast pathologists from the same institution reviewed 60 HER2 IHC stains on breast biopsy specimens in 2 rounds of 30 cases each. An educational slide review session was provided between the 2 rounds. Interobserver Cohen κ values were computed and compared.Results: Overall complete agreement for HER2 IHC was noted in 37 (62%) of 60 cases, with similar agreement in the first round (19/30 [63%]) and second round (18/30 [60%]). For all 60 cases, κ values ranged from .517 to .895, with 92% of κ values in substantial agreement or better range. For combined HER2-0 and HER2-L cases, κ values ranged from .298 to .826, with only 45% of κ values in substantial agreement or better range. In HER2-L only cases, 50% of the scorer pairs of κ values were 0 or less (no agreement), and only 14% of pairs showed substantial or better agreement. The educational session did not improve the κ values. Faint and heterogeneous HER2 expression, cytoplasmic blush, dislodged cells, and in situ component led to poor concordance in HER2-0 vs HER2-L.Conclusions: Poor concordance on HER2-0 vs HER2-L and lack of improvement after a training session likely suggest ineffective HER2 IHC expression range in HER2 low spectrum.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"244-256"},"PeriodicalIF":1.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sensitivity and specificity of immunohistochemistry for the diagnosis of filamentous fungal infections. 免疫组织化学诊断丝状真菌感染的敏感性和特异性。

IF 1.9 4区医学

American journal of clinical pathology Pub Date : 2025-08-26 DOI: 10.1093/ajcp/aqaf037

Victoria L Thomas, Alvaro C Laga, Isaac H Solomon

{"title":"Sensitivity and specificity of immunohistochemistry for the diagnosis of filamentous fungal infections.","authors":"Victoria L Thomas, Alvaro C Laga, Isaac H Solomon","doi":"10.1093/ajcp/aqaf037","DOIUrl":"10.1093/ajcp/aqaf037","url":null,"abstract":"Objectives: Many fungal species share overlapping morphologic features in tissue sections, preventing reliable identification and optimal treatment. We sought to determine whether immunohistochemistry (IHC) using a panel of commercially available antibodies could effectively distinguish between fungi commonly encountered in anatomic pathology specimens.Methods: Anti-Aspergillus, anti-Rhizopus, and anti-Candida IHC was performed on formalin-fixed, paraffin-embedded tissue sections from 24 cases with fungal infections identified by culture or sequencing (including 4 polyfungal infections).Results: Anti-Aspergillus IHC was positive in 6 of 6 Aspergillus and focally in 1 of 4 Candida species infections and negative in all cases of Fusarium, Scedosporium, Rhizopus, and Mucor species, yielding overall sensitivity of 100% and specificity of 95%. Anti-Rhizopus IHC was positive in 4 of 4 Rhizopus and 1 of 3 Mucor species infections and negative in all other cases, with a sensitivity of 71% and a specificity of 100%. Anti-Candida IHC was positive in 4 of 4 Candida species infections and showed some cross-reactivity in all other cases, resulting in 100% sensitivity and 0% specificity.Conclusions: Anti-Aspergillus IHC was highly sensitive and specific in its ability to distinguish Aspergillus from other similar-appearing hyaline molds, including Fusarium and Scedosporium species. Anti-Rhizopus IHC was moderately sensitive and highly specific, while anti-Candida IHC was highly sensitive but had minimal specificity.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"216-225"},"PeriodicalIF":1.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cutaneous lupus erythematosus presenting as a nonhealing ulcer in an African American woman: A case report. 皮肤红斑狼疮表现为非裔美国妇女无法愈合的溃疡：一例报告。

IF 1.9 4区医学

American journal of clinical pathology Pub Date : 2025-08-26 DOI: 10.1093/ajcp/aqaf017

Kevin M Burningham, Mohamad Taha, Seo Won Cho, Mahmud Alkul, Anisha B Patel, Stephen K Tyring

引用次数: 0

Impact of PlGF immunoassay imprecision on preeclampsia risk assessment with the sFlt-1 to PlGF ratio. 用sFlt-1 / PlGF比值评估PlGF免疫测定不精确性对子痫前期风险评估的影响

IF 1.9 4区医学

American journal of clinical pathology Pub Date : 2025-08-26 DOI: 10.1093/ajcp/aqaf032

Guanmin Chen, Clarence W Chan, Richard F Schaefer, Sarosh Rana, Kiang-Teck J Yeo

{"title":"Impact of PlGF immunoassay imprecision on preeclampsia risk assessment with the sFlt-1 to PlGF ratio.","authors":"Guanmin Chen, Clarence W Chan, Richard F Schaefer, Sarosh Rana, Kiang-Teck J Yeo","doi":"10.1093/ajcp/aqaf032","DOIUrl":"10.1093/ajcp/aqaf032","url":null,"abstract":"Objective: The US Food and Drug Administration recently approved the ratio of soluble FMS-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) using the Thermo Fisher Scientific B·R·A·H·M·S KRYPTOR autoanalyzer-the first preeclampsia marker used for clinical testing. We evaluated the analytical precision of the sFlt-1 and PlGF assays, focusing on the effects of PlGF imprecision on the sFlt-1 to PlGF ratio interpretation and clinical reliability for preeclampsia risk assessment.Methods: We measured sFlt-1 and PlGF on the KRYPTOR instrument using a homogeneous sandwich fluoroimmunoassay. Between-day precision was assessed using 3 levels of commercial quality control (QC) materials and analyzed over 3 months. In all, 180 samples obtained from 161 hospitalized pregnant women were analyzed to assess the relationship between PlGF levels and the sFlt-1 to PlGF ratio.Results: The sFlt-1 assay demonstrated good precision (coefficient of variation (s/x̄) × 100 [CV] = approximately 3.0%) across all QC levels, while the PlGF assay exhibited higher imprecision, particularly at low QC levels (CV = 7.7%-11.3%). Long-term QC monitoring revealed a downward drift in PlGF values, with improved stability after reagent lot changes. Despite higher imprecision at lower PlGF levels (23.1-34.7 ng/L), the clinical interpretation of the sFlt-1 to PlGF ratio remained robust because low PlGF consistently correlated with ratios well above the critical cutoff of 40.Conclusions: Despite the suboptimal precision observed at low QC levels and potential drifts in PlGF results, the sFlt-1 to PlGF ratio remains a reliable tool for preeclampsia risk assessment. This study highlights the need for critical evaluation of analytical performance beyond FDA approval and the importance of assessing the potential impact of assay imprecision on patient care for individual biomarkers.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"200-206"},"PeriodicalIF":1.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

p53abn high-risk endometrial cancer with PPP2R1A mutation might not benefit from adjuvant chemotherapy. 伴有PPP2R1A突变的p53abn高危子宫内膜癌可能无法从辅助化疗中获益。

IF 1.9 4区医学

American journal of clinical pathology Pub Date : 2025-08-26 DOI: 10.1093/ajcp/aqaf039

Qingxia Zhang, Yue Wang, Dan He, Jingyun Sun, Xin Li, Dong Li, Ying Dong, Yan Zhang, Suxia Wang

{"title":"p53abn high-risk endometrial cancer with PPP2R1A mutation might not benefit from adjuvant chemotherapy.","authors":"Qingxia Zhang, Yue Wang, Dan He, Jingyun Sun, Xin Li, Dong Li, Ying Dong, Yan Zhang, Suxia Wang","doi":"10.1093/ajcp/aqaf039","DOIUrl":"10.1093/ajcp/aqaf039","url":null,"abstract":"Objectives: Recent studies have found that high-risk endometrial cancer frequently harbors mutations in tumor suppressor genes PPP2R1A and FBXW7. This study aimed to explore the prognostic utility of these genes and their potential to predict benefit from adjuvant treatment.Methods: Tissue samples of 121 patients with high-risk endometrial cancer were collected. PPP2R1A, FBXW7, and POLE exonuclease domain mutations were detected using Sanger sequencing, while mismatch repair proteins and p53 expression were tested by immunohistochemistry.Results: PPP2R1A and FBXW7 mutations were detected in 11.6% and 21.5% of tumors, respectively. PPP2R1A mutations occurred more frequently in nonendometrioid, high-grade, and advanced-stage tumors and were strongly correlated with poor prognosis. Importantly, PPP2R1A mutations were more frequent in the p53 abnormal (p53abn) subgroup than in the other 3 molecular subgroups (P = .011). In addition, patients with p53abn, PPP2R1A-mutated tumors showed poor prognosis regardless of whether they received adjuvant chemotherapy. In contrast, patients with p53abn, PPP2R1A wild-type tumors exhibited statistically significantly longer survival after adjuvant chemotherapy (P = .022). Similar associations were observed in the patients with p53abn, FBWX7 wild-type tumors.Conclusions: PPP2R1A and FBXW7 status may be related to the current adjuvant chemotherapy outcome, particularly in endometrial cancer with the p53abn subtype. Thus, incorporating PPP2R1A and FBXW7 detection in the stratification and treatment decision-making process may be helpful.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"233-243"},"PeriodicalIF":1.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Haptoglobin in pregnancy: Trimester-specific reference intervals. 妊娠期的珠蛋白：妊娠期特异性参考区间。

IF 1.9 4区医学

American journal of clinical pathology Pub Date : 2025-08-26 DOI: 10.1093/ajcp/aqaf012

M Natalia Chaves Rivera, Ibrahim Choucair, Michael A Vera, Edward S Lee, Joe M El-Khoury, Cristina A Figueroa Villalba

{"title":"Haptoglobin in pregnancy: Trimester-specific reference intervals.","authors":"M Natalia Chaves Rivera, Ibrahim Choucair, Michael A Vera, Edward S Lee, Joe M El-Khoury, Cristina A Figueroa Villalba","doi":"10.1093/ajcp/aqaf012","DOIUrl":"10.1093/ajcp/aqaf012","url":null,"abstract":"Objectives: Pregnancy induces physiologic changes that can affect serologic and immunologic markers, potentially resulting in lower haptoglobin values than nonpregnant counterparts. Such variations may lead to concern for hemolysis in pregnancy. This study aims to analyze reference intervals (RIs) for haptoglobin in each trimester of pregnancy.Methods: We employed a quality improvement project to analyze a total of 401 remnant serum samples (BD Vacutainer SST) collected from routine outpatient pregnancy patients. Roche Cobas 8000 (c 502) systems were used to examine at least 80 samples per trimester: first trimester (86 samples), second trimester (230 samples), and third trimester (80 samples). Haptoglobin between trimesters was compared using the Mann-Whitney test.Results: Nonparametric RIs were calculated to be 27 to 196 mg/dL for the first trimester, 27 to 178 mg/dL for the second trimester, 34 to 191 mg/dL for the third trimester, and 30 to 185 mg/dL for the entire sample population. The distribution of second-trimester haptoglobin (median, 98 mg/dL) was significantly different compared to the first trimester (median, 113.5 mg/dL; P < .05) and the third trimester (median, 112.5 mg/dL; P < .05).Conclusions: Although overall haptoglobin RI during pregnancy aligned with the nonpregnant population, our study revealed a significant shift during the second trimester. This finding suggests that pregnant individuals in the second trimester may have lower haptoglobin values and potentially be misdiagnosed with intravascular hemolysis when consequent added factors further decrease haptoglobin below the level of detection without hemolysis.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"150-153"},"PeriodicalIF":1.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epstein-Barr virus-positive T- and NK-cell lymphoproliferative disorders: Report from the 2023 SH/EA4HP Lymphoma Workshop. eb病毒阳性T细胞和nk细胞淋巴增生性疾病：来自2023年SH/EA4HP淋巴瘤研讨会的报告

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2025-07-11 DOI: 10.1093/ajcp/aqaf020

Leticia Quintanilla-Martinez, Shaoying Li, Amy Chadburn

{"title":"Epstein-Barr virus-positive T- and NK-cell lymphoproliferative disorders: Report from the 2023 SH/EA4HP Lymphoma Workshop.","authors":"Leticia Quintanilla-Martinez, Shaoying Li, Amy Chadburn","doi":"10.1093/ajcp/aqaf020","DOIUrl":"10.1093/ajcp/aqaf020","url":null,"abstract":"Objectives: To summarize the conclusions of the 2023 Society for Hematopathology/European Association for Haematopathology workshop regarding Epstein-Barr virus (EBV)-positive T- and natural killer (NK)-cell lymphoproliferative disorders (LPDs).Methods: There were 38 cases submitted to session 3 of the workshop.Results: Cases included extranodal NK/T-cell lymphoma (ENKTCL), nasal type (n = 16), EBV+ T- and NK-cell LPDs in children (n = 12), primary nodal EBV+ T- and NK-cell lymphoma (n = 5), and other EBV+ T- and NK-cell LPDs (n = 5). The ENKTCL cases highlighted some unusual features like indolent behavior, small cell morphology, and T-cell phenotype, including cases with CD4 and CD30 expression. The differential diagnosis of ENKTCL was illustrated by 4 cases with other primary cutaneous lymphomas. The difficulty in the diagnosis of systemic chronic active EBV disease, its complications, and the sometimes elusive boundaries among the EBV+ LPDs in children are also discussed. The submitted cases also unveiled cases of EBV+ γδ T-cell leukemia/lymphoma not recognized under current classifications and cases of EBV+ CD8+ cytotoxic lymphomas associated with treatment for B-cell lymphomas. The need to have a low threshold to investigate the presence of EBV is highlighted.Conclusions: The diagnosis of EBV+ T- and NK-cell LPDs is complex and requires a multiparameter approach incorporating clinical information and morphologic and molecular features.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"46-64"},"PeriodicalIF":2.3,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0